The Middle East & Africa influenza vaccines market is expected to grow from US$ 374.35 million in 2022 to US$ 533.85 million by 2028; it is estimated to grow at a CAGR of 6.1% from 2022 to 2028.
Increase in Government Support to Promote Influenza Vaccination to Bolster Middle East & Africa Influenza Vaccines Market During Forecast Period
Leading players in the influenza vaccines market have multiple projects on drug delivery and biological pipelines based on proprietary technology. The most advanced candidate population in drug delivery completed 2 Phase I studies. The pipeline also includes a large number of compounds that have completed preclinical evaluation. Pipeline candidates are focused on unlocking the science of the immune system, human genetics, and cutting-edge technologies to develop innovative vaccines. Companies are investing in scientific and technical excellence to develop and introduce new vaccines and specific drugs against infectious diseases, including influenza. Vaccines and viral therapeutic candidates in the pipeline are capable of rapidly and specifically responding to the most pressing health threats in the Middle East & Africa. Thus, strong pipeline candidates for influenza vaccines are the latest trend in the Middle East & Africa influenza vaccines market.
Market Overview
The Middle East & Africa influenza vaccines market is segmented into the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. In 2022, South Africa was the largest market for influenza vaccines in the region. The market for influenza vaccines in the Middle East & Africa is anticipated to grow at a CAGR of 6.1% during the forecast period. The influenza vaccines market is expected to grow due to the rising population base, increasing cases of influenza, growing research studies across the region, and increasing healthcare facilities.
Middle East & Africa Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Million)
Middle East & Africa Influenza Vaccines Market Segmentation
The Middle East & Africa influenza vaccines market is segmented on the basis of vaccine type, virus type, technology, route of administration, target group, and country.
Based on vaccine type, the Middle East & Africa influenza vaccines market is bifurcated into quadrivalent vaccines and trivalent vaccines. The quadrivalent vaccines segment registered a larger share of the market in 2022.
Based on virus type, the Middle East & Africa influenza vaccines market is bifurcated into influenza virus type A and influenza virus type B. The influenza virus type A segment held a larger share of the market in 2022.
Based on technology, the Middle East & Africa influenza vaccines market is divided into egg-based and cell-based. The egg-based segment held a larger share of the market in 2022.
Based on route of administration, the Middle East & Africa influenza vaccines market is divided into injection and nasal spray. The injection segment held a larger share of the market in 2022.
Based on target group, the Middle East & Africa influenza vaccines market is segmented into infants, children, adults, and elderly people. The infants segment held the largest share of the market in 2022.
Based on country, the Middle East & Africa influenza vaccines market is segmented into Saudi Arabia, the UAE, South Africa, and the Rest of Middle East & Africa. Saudi Arabia dominated the market in 2022.
AstraZeneca; GlaxoSmithKline plc.; Mitsubishi Chemical Group Corporation; MYLAN N.V.; Sanofi; SEQIRUS; and Serum Institute of India Pvt. Ltd are the leading companies operating in the Middle East & Africa influenza vaccines market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 374.35 Million |
| Market Size by 2028 | US$ 533.85 Million |
| CAGR (2022 - 2028) | 6.1% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Vaccine Type
|
| Regions and Countries Covered |
Middle East and Africa
|
| Market leaders and key company profiles |
|
The Middle East & Africa Influenza Vaccines Market is valued at US$ 374.35 Million in 2022, it is projected to reach US$ 533.85 Million by 2028.
As per our report Middle East & Africa Influenza Vaccines Market, the market size is valued at US$ 374.35 Million in 2022, projecting it to reach US$ 533.85 Million by 2028. This translates to a CAGR of approximately 6.1% during the forecast period.
The Middle East & Africa Influenza Vaccines Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Middle East & Africa Influenza Vaccines Market report:
The Middle East & Africa Influenza Vaccines Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Middle East & Africa Influenza Vaccines Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Middle East & Africa Influenza Vaccines Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Middle East & Africa Influenza Vaccines Market
